Abstract
SARS COV-2 and its related disease COVID 19 has led to a major global
pandemic and in absence of no known effective therapeutic agents against
it, virus is having a free run. Sequence analyses, homology modelling
and docking have suggested potential drugs which can be used against
this virus. Sofosubivir is a direct-acting antiviral agent with NS5B
RNA-dependent RNA polymerase (RdRp) inhibitory activity used in
management of Hepatitis-C infection. This drug has potential role in
managing this viral disease. Safety and efficacy of this drug is already
established in patients of Hepatitis-C where it is given for long
periods of time. Favourable pharmacokinetic profile of this drug also
favors it use in this infection. This report summarises information
available which can be explored further in clinical trials.